Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 11 of 11 entries
Sorted by: Best Match Show Resources per page
Blood pressure, dyslipidemia and inflammatory factors are related to body mass index in scholar adolescents.

Archives of medical science : AMS

Ghomari-Boukhatem H, Bouchouicha A, Mekki K, Chenni K, Belhadj M, Bouchenak M.
PMID: 28144254
Arch Med Sci. 2017 Feb 01;13(1):46-52. doi: 10.5114/aoms.2017.64713. Epub 2016 Dec 19.

INTRODUCTION: Obesity is associated with increased occurrence of numerous diseases, including hypertension, dyslipidemia, insulin resistance, diabetes, and atherosclerosis. Blood pressure (BP), dyslipidemia, and inflammation markers and their relationships with body mass index (BMI) were determined in scholar adolescents.MATERIAL AND...

Cite
Ghomari-Boukhatem H, Bouchouicha A, Mekki K, et al. Blood pressure, dyslipidemia and inflammatory factors are related to body mass index in scholar adolescents. Arch Med Sci. 2016;13(1):46-52doi: 10.5114/aoms.2017.64713.
Ghomari-Boukhatem, H., Bouchouicha, A., Mekki, K., Chenni, K., Belhadj, M., & Bouchenak, M. (2017). Blood pressure, dyslipidemia and inflammatory factors are related to body mass index in scholar adolescents. Archives of medical science : AMS, 13(1), 46-52. https://doi.org/10.5114/aoms.2017.64713
Ghomari-Boukhatem, Hanane, et al. "Blood pressure, dyslipidemia and inflammatory factors are related to body mass index in scholar adolescents." Archives of medical science : AMS vol. 13,1 (2017): 46-52. doi: https://doi.org/10.5114/aoms.2017.64713
Ghomari-Boukhatem H, Bouchouicha A, Mekki K, Chenni K, Belhadj M, Bouchenak M. Blood pressure, dyslipidemia and inflammatory factors are related to body mass index in scholar adolescents. Arch Med Sci. 2017 Feb 01;13(1):46-52. doi: 10.5114/aoms.2017.64713. Epub 2016 Dec 19. PMID: 28144254; PMCID: PMC5206370.
Copy Download .nbib Format: NLM
Fuchs' Uveitis: Failure to Associate Vitritis and Disc Hyperfluorescence with the Disease is the Major Factor for Misdiagnosis and Diagnostic Delay.

Middle East African journal of ophthalmology

Bouchenaki N, Herbort CP.
PMID: 20404990
Middle East Afr J Ophthalmol. 2009 Oct;16(4):239-44. doi: 10.4103/0974-9233.58424.

PURPOSE: Fuchs' uveitis is often diagnosed with substantial delay at the origin of deleterious consequences such as unnecessary treatment. The aim of the study was to analyse the type and frequency of posterior inflammatory and fluorescein angiographic signs in...

Cite
Bouchenaki N, Herbort CP. Fuchs' Uveitis: Failure to Associate Vitritis and Disc Hyperfluorescence with the Disease is the Major Factor for Misdiagnosis and Diagnostic Delay. Middle East Afr J Ophthalmol. 2009;16(4):239-44doi: 10.4103/0974-9233.58424.
Bouchenaki, N., & Herbort, C. P. (2009). Fuchs' Uveitis: Failure to Associate Vitritis and Disc Hyperfluorescence with the Disease is the Major Factor for Misdiagnosis and Diagnostic Delay. Middle East African journal of ophthalmology, 16(4), 239-44. https://doi.org/10.4103/0974-9233.58424
Bouchenaki, Nadia, and Herbort, Carl P. "Fuchs' Uveitis: Failure to Associate Vitritis and Disc Hyperfluorescence with the Disease is the Major Factor for Misdiagnosis and Diagnostic Delay." Middle East African journal of ophthalmology vol. 16,4 (2009): 239-44. doi: https://doi.org/10.4103/0974-9233.58424
Bouchenaki N, Herbort CP. Fuchs' Uveitis: Failure to Associate Vitritis and Disc Hyperfluorescence with the Disease is the Major Factor for Misdiagnosis and Diagnostic Delay. Middle East Afr J Ophthalmol. 2009 Oct;16(4):239-44. doi: 10.4103/0974-9233.58424. PMID: 20404990; PMCID: PMC2855664.
Copy Download .nbib Format: NLM
Effect of different stages of chronic kidney disease and renal replacement therapies on oxidant-antioxidant balance in uremic patients.

Biochemistry research international

Tbahriti HF, Kaddous A, Bouchenak M, Mekki K.
PMID: 24416590
Biochem Res Int. 2013;2013:358985. doi: 10.1155/2013/358985. Epub 2013 Dec 12.

Oxidative stress seems to be involved in the path physiology of cardiovascular complications of chronic kidney disease (CKD). In this study, we determined the effect of different stages of CKD and substitutive therapies on oxidative stress. One hundred sixty-seven...

Cite
Tbahriti HF, Kaddous A, Bouchenak M, et al. Effect of different stages of chronic kidney disease and renal replacement therapies on oxidant-antioxidant balance in uremic patients. Biochem Res Int. 2013;2013:358985doi: 10.1155/2013/358985.
Tbahriti, H. F., Kaddous, A., Bouchenak, M., & Mekki, K. (2013). Effect of different stages of chronic kidney disease and renal replacement therapies on oxidant-antioxidant balance in uremic patients. Biochemistry research international, 2013358985. https://doi.org/10.1155/2013/358985
Tbahriti, Hadja Fatima, et al. "Effect of different stages of chronic kidney disease and renal replacement therapies on oxidant-antioxidant balance in uremic patients." Biochemistry research international vol. 2013 (2013): 358985. doi: https://doi.org/10.1155/2013/358985
Tbahriti HF, Kaddous A, Bouchenak M, Mekki K. Effect of different stages of chronic kidney disease and renal replacement therapies on oxidant-antioxidant balance in uremic patients. Biochem Res Int. 2013;2013:358985. doi: 10.1155/2013/358985. Epub 2013 Dec 12. PMID: 24416590; PMCID: PMC3876691.
Copy Download .nbib Format: NLM
The Angiotensin II Type 2 Receptor, a Target for Protection and Regeneration of the Peripheral Nervous System?.

Pharmaceuticals (Basel, Switzerland)

Danigo A, Rovini A, Bessaguet F, Bouchenaki H, Bernard A, Sturtz F, Bourthoumieu S, Desmoulière A, Magy L, Demiot C.
PMID: 33668331
Pharmaceuticals (Basel). 2021 Feb 24;14(3). doi: 10.3390/ph14030175.

Preclinical evidence, accumulated over the past decade, indicates that the angiotensin II type 2 receptor (AT2R) stimulation exerts significant neuroprotective effects in various animal models of neuronal injury, notably in the central nervous system. While the atypical G protein-coupled...

Cite
Danigo A, Rovini A, Bessaguet F, et al. The Angiotensin II Type 2 Receptor, a Target for Protection and Regeneration of the Peripheral Nervous System?. Pharmaceuticals (Basel). 2021;14(3)doi: 10.3390/ph14030175.
Danigo, A., Rovini, A., Bessaguet, F., Bouchenaki, H., Bernard, A., Sturtz, F., Bourthoumieu, S., Desmoulière, A., Magy, L., & Demiot, C. (2021). The Angiotensin II Type 2 Receptor, a Target for Protection and Regeneration of the Peripheral Nervous System?. Pharmaceuticals (Basel, Switzerland), 14(3), . https://doi.org/10.3390/ph14030175
Danigo, Aurore, et al. "The Angiotensin II Type 2 Receptor, a Target for Protection and Regeneration of the Peripheral Nervous System?." Pharmaceuticals (Basel, Switzerland) vol. 14,3 (2021). doi: https://doi.org/10.3390/ph14030175
Danigo A, Rovini A, Bessaguet F, Bouchenaki H, Bernard A, Sturtz F, Bourthoumieu S, Desmoulière A, Magy L, Demiot C. The Angiotensin II Type 2 Receptor, a Target for Protection and Regeneration of the Peripheral Nervous System?. Pharmaceuticals (Basel). 2021 Feb 24;14(3). doi: 10.3390/ph14030175. PMID: 33668331; PMCID: PMC7996246.
Copy Download .nbib Format: NLM
Indocyanine green angiography guided management of vogt-koyanagi-harada disease.

Journal of ophthalmic & vision research

Bouchenaki N, Herbort CP.
PMID: 22454746
J Ophthalmic Vis Res. 2011 Oct;6(4):241-8.

PURPOSE: To report the management of Vogt-Koyanagi-Harada (VKH) disease based on indocyanine green angiography (ICGA).METHODS: VKH patients with acute episodes of inflammation (inaugural or recurrent) who had received standard ICGA-guided care were studied retrospectively. Standard of care included high...

Cite
Bouchenaki N, Herbort CP. Indocyanine green angiography guided management of vogt-koyanagi-harada disease. J Ophthalmic Vis Res. 2011;6(4):241-8
Bouchenaki, N., & Herbort, C. P. (2011). Indocyanine green angiography guided management of vogt-koyanagi-harada disease. Journal of ophthalmic & vision research, 6(4), 241-8.
Bouchenaki, Nadia, and Herbort, Carl P. "Indocyanine green angiography guided management of vogt-koyanagi-harada disease." Journal of ophthalmic & vision research vol. 6,4 (2011): 241-8.
Bouchenaki N, Herbort CP. Indocyanine green angiography guided management of vogt-koyanagi-harada disease. J Ophthalmic Vis Res. 2011 Oct;6(4):241-8. PMID: 22454746; PMCID: PMC3306120.
Copy Download .nbib Format: NLM
Indocyanine green angiography guided management of vogt-koyanagi-harada disease.

Journal of ophthalmic & vision research

Bouchenaki N, Herbort CP.
PMID: 22454746
J Ophthalmic Vis Res. 2011 Oct;6(4):241-8.

PURPOSE: To report the management of Vogt-Koyanagi-Harada (VKH) disease based on indocyanine green angiography (ICGA).METHODS: VKH patients with acute episodes of inflammation (inaugural or recurrent) who had received standard ICGA-guided care were studied retrospectively. Standard of care included high...

Cite
Bouchenaki N, Herbort CP. Indocyanine green angiography guided management of vogt-koyanagi-harada disease. J Ophthalmic Vis Res. 2011;6(4):241-8
Bouchenaki, N., & Herbort, C. P. (2011). Indocyanine green angiography guided management of vogt-koyanagi-harada disease. Journal of ophthalmic & vision research, 6(4), 241-8.
Bouchenaki, Nadia, and Herbort, Carl P. "Indocyanine green angiography guided management of vogt-koyanagi-harada disease." Journal of ophthalmic & vision research vol. 6,4 (2011): 241-8.
Bouchenaki N, Herbort CP. Indocyanine green angiography guided management of vogt-koyanagi-harada disease. J Ophthalmic Vis Res. 2011 Oct;6(4):241-8. PMID: 22454746; PMCID: PMC3306120.
Copy Download .nbib Format: NLM
An overview of ongoing clinical trials assessing pharmacological therapeutic strategies to manage chemotherapy-induced peripheral neuropathy, based on preclinical studies in rodent models.

Fundamental & clinical pharmacology

Bouchenaki H, Danigo A, Sturtz F, Hajj R, Magy L, Demiot C.
PMID: 33107619
Fundam Clin Pharmacol. 2021 Jun;35(3):506-523. doi: 10.1111/fcp.12617. Epub 2020 Dec 02.

Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect induced by a variety of chemotherapeutic agents. Symptoms are mainly sensory: pain, tingling, numbness, and temperature sensitivity. They may require the tapering of chemotherapy regimens or even their cessation;...

Cite
Bouchenaki H, Danigo A, Sturtz F, et al. An overview of ongoing clinical trials assessing pharmacological therapeutic strategies to manage chemotherapy-induced peripheral neuropathy, based on preclinical studies in rodent models. Fundam Clin Pharmacol. 2020;35(3):506-523doi: 10.1111/fcp.12617.
Bouchenaki, H., Danigo, A., Sturtz, F., Hajj, R., Magy, L., & Demiot, C. (2021). An overview of ongoing clinical trials assessing pharmacological therapeutic strategies to manage chemotherapy-induced peripheral neuropathy, based on preclinical studies in rodent models. Fundamental & clinical pharmacology, 35(3), 506-523. https://doi.org/10.1111/fcp.12617
Bouchenaki, Hichem, et al. "An overview of ongoing clinical trials assessing pharmacological therapeutic strategies to manage chemotherapy-induced peripheral neuropathy, based on preclinical studies in rodent models." Fundamental & clinical pharmacology vol. 35,3 (2021): 506-523. doi: https://doi.org/10.1111/fcp.12617
Bouchenaki H, Danigo A, Sturtz F, Hajj R, Magy L, Demiot C. An overview of ongoing clinical trials assessing pharmacological therapeutic strategies to manage chemotherapy-induced peripheral neuropathy, based on preclinical studies in rodent models. Fundam Clin Pharmacol. 2021 Jun;35(3):506-523. doi: 10.1111/fcp.12617. Epub 2020 Dec 02. PMID: 33107619.
Copy Download .nbib Format: NLM
Inflammatory status in chronic renal failure: The role of homocysteinemia and pro-inflammatory cytokines.

World journal of nephrology

Tbahriti HF, Meknassi D, Moussaoui R, Messaoudi A, Zemour L, Kaddous A, Bouchenak M, Mekki K.
PMID: 24175263
World J Nephrol. 2013 May 06;2(2):31-7. doi: 10.5527/wjn.v2.i2.31.

AIM: To evaluate determinants of inflammatory markers in chronic renal failure patients according to the level of glomerular filtration rate.METHODS: One hundred fifty four patients (Age: 44 ± 06 years; male/female: 66/88) with chronic renal failure (CRF) were divided...

Cite
Tbahriti HF, Meknassi D, Moussaoui R, et al. Inflammatory status in chronic renal failure: The role of homocysteinemia and pro-inflammatory cytokines. World J Nephrol. 2013;2(2):31-7doi: 10.5527/wjn.v2.i2.31.
Tbahriti, H. F., Meknassi, D., Moussaoui, R., Messaoudi, A., Zemour, L., Kaddous, A., Bouchenak, M., & Mekki, K. (2013). Inflammatory status in chronic renal failure: The role of homocysteinemia and pro-inflammatory cytokines. World journal of nephrology, 2(2), 31-7. https://doi.org/10.5527/wjn.v2.i2.31
Tbahriti, Hadja Fatima, et al. "Inflammatory status in chronic renal failure: The role of homocysteinemia and pro-inflammatory cytokines." World journal of nephrology vol. 2,2 (2013): 31-7. doi: https://doi.org/10.5527/wjn.v2.i2.31
Tbahriti HF, Meknassi D, Moussaoui R, Messaoudi A, Zemour L, Kaddous A, Bouchenak M, Mekki K. Inflammatory status in chronic renal failure: The role of homocysteinemia and pro-inflammatory cytokines. World J Nephrol. 2013 May 06;2(2):31-7. doi: 10.5527/wjn.v2.i2.31. PMID: 24175263; PMCID: PMC3782222.
Copy Download .nbib Format: NLM
Ramipril Alleviates Oxaliplatin-Induced Acute Pain Syndrome in Mice.

Frontiers in pharmacology

Bouchenaki H, Danigo A, Bernard A, Bessaguet F, Richard L, Sturtz F, Balayssac D, Magy L, Demiot C.
PMID: 34349658
Front Pharmacol. 2021 Jul 19;12:712442. doi: 10.3389/fphar.2021.712442. eCollection 2021.

Oxaliplatin is a key drug for colorectal cancer that causes OXP-induced peripheral neuropathy, a dose-limiting effect characterized by cold and tactile hyperesthesia. The relationship between the sensory nervous system and modulation of the renin-angiotensin system has been described, focusing...

Cite
Bouchenaki H, Danigo A, Bernard A, et al. Ramipril Alleviates Oxaliplatin-Induced Acute Pain Syndrome in Mice. Front Pharmacol. 2021;12:712442doi: 10.3389/fphar.2021.712442.
Bouchenaki, H., Danigo, A., Bernard, A., Bessaguet, F., Richard, L., Sturtz, F., Balayssac, D., Magy, L., & Demiot, C. (2021). Ramipril Alleviates Oxaliplatin-Induced Acute Pain Syndrome in Mice. Frontiers in pharmacology, 12712442. https://doi.org/10.3389/fphar.2021.712442
Bouchenaki, Hichem, et al. "Ramipril Alleviates Oxaliplatin-Induced Acute Pain Syndrome in Mice." Frontiers in pharmacology vol. 12 (2021): 712442. doi: https://doi.org/10.3389/fphar.2021.712442
Bouchenaki H, Danigo A, Bernard A, Bessaguet F, Richard L, Sturtz F, Balayssac D, Magy L, Demiot C. Ramipril Alleviates Oxaliplatin-Induced Acute Pain Syndrome in Mice. Front Pharmacol. 2021 Jul 19;12:712442. doi: 10.3389/fphar.2021.712442. eCollection 2021. PMID: 34349658; PMCID: PMC8326755.
Copy Download .nbib Format: NLM
Lifestyle advice follow-up improve glycemic control, redox and inflammatory status in patients with type 2 diabetes.

Journal of diabetes and metabolic disorders

Mahdad N, Boukortt FO, Benzian Z, Bouchenak M.
PMID: 25551102
J Diabetes Metab Disord. 2014 Dec 17;13(1):122. doi: 10.1186/s40200-014-0122-1. eCollection 2014.

BACKGROUND: The dietary composition associated to physical activity could play a significant role in improving insulin sensitivity and reducing risk of diabetes and its complications. This study was designed to investigate whether glycemic control, redox and inflammatory status impairments...

Cite
Mahdad N, Boukortt FO, Benzian Z, et al. Lifestyle advice follow-up improve glycemic control, redox and inflammatory status in patients with type 2 diabetes. J Diabetes Metab Disord. 2014;13(1):122doi: 10.1186/s40200-014-0122-1.
Mahdad, N., Boukortt, F. O., Benzian, Z., & Bouchenak, M. (2014). Lifestyle advice follow-up improve glycemic control, redox and inflammatory status in patients with type 2 diabetes. Journal of diabetes and metabolic disorders, 13(1), 122. https://doi.org/10.1186/s40200-014-0122-1
Mahdad, Nadia, et al. "Lifestyle advice follow-up improve glycemic control, redox and inflammatory status in patients with type 2 diabetes." Journal of diabetes and metabolic disorders vol. 13,1 (2014): 122. doi: https://doi.org/10.1186/s40200-014-0122-1
Mahdad N, Boukortt FO, Benzian Z, Bouchenak M. Lifestyle advice follow-up improve glycemic control, redox and inflammatory status in patients with type 2 diabetes. J Diabetes Metab Disord. 2014 Dec 17;13(1):122. doi: 10.1186/s40200-014-0122-1. eCollection 2014. PMID: 25551102; PMCID: PMC4279685.
Copy Download .nbib Format: NLM
Acaricidal activity of flavonoids extract of Borago officinalis L. (Boraginaceae) against brown dog tick, Rhipicephalus sanguineus (Latreille, 1806).

Tropical biomedicine

El Haddad D, Bitam I, Bouchenak O, Toubal S, Yahiaoui K, Arab K, Boumaza S.
PMID: 33601812
Trop Biomed. 2018 Jun 01;35(2):383-391.

Borago officinalis L. (Boraginaceae) is a plant of the Boraginaceae family, used in Algeria for food and medicinal purposes. This study reports the effect of flavonoids extracted from the aerial part of Borago officinalis L. (Boraginaceae) on the larvae...

Cite
El Haddad D, Bitam I, Bouchenak O, et al. Acaricidal activity of flavonoids extract of Borago officinalis L. (Boraginaceae) against brown dog tick, Rhipicephalus sanguineus (Latreille, 1806). Trop Biomed. 2018;35(2):383-391
El Haddad, D., Bitam, I., Bouchenak, O., Toubal, S., Yahiaoui, K., Arab, K., & Boumaza, S. (2018). Acaricidal activity of flavonoids extract of Borago officinalis L. (Boraginaceae) against brown dog tick, Rhipicephalus sanguineus (Latreille, 1806). Tropical biomedicine, 35(2), 383-391.
El Haddad, D, et al. "Acaricidal activity of flavonoids extract of Borago officinalis L. (Boraginaceae) against brown dog tick, Rhipicephalus sanguineus (Latreille, 1806)." Tropical biomedicine vol. 35,2 (2018): 383-391.
El Haddad D, Bitam I, Bouchenak O, Toubal S, Yahiaoui K, Arab K, Boumaza S. Acaricidal activity of flavonoids extract of Borago officinalis L. (Boraginaceae) against brown dog tick, Rhipicephalus sanguineus (Latreille, 1806). Trop Biomed. 2018 Jun 01;35(2):383-391. PMID: 33601812.
Copy Download .nbib Format: NLM
Showing 1 to 11 of 11 entries